| ‘State of the art’of radical hysterectomy; current practice in European oncology centres JB Trimbos, M Franchi, F Zanaboni, JVD Velden, I Vergote European journal of cancer 40 (3), 375-378, 2004 | 55 | 2004 |
| " Phase III randomised study to evaluate the role of a uvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II:: An European organisation for research … NS Reed, C Mangioni, H Malmstroem, G Scarfone, A Poveda, S Pecorelli, ... European Journal Of Cancer 44 (11), 1612-1612, 2008 | 1 | 2008 |
| # 1350 Tumor treating fields (TTFields) therapy in platinum-resistant ovarian cancer: results from the ENGOT-ov50/GOG-3029/INNOVATE-3 phase 3 study I Vergote, L Copeland, T Van Gorp, A Laenen, G Scambia, PH Thaker, ... International Journal of Gynecologic Cancer 34 (Suppl 1), 2024 | | 2024 |
| # 264 Long-term follow up of selinexor maintenance for patients with TP53wt advanced or recurrent endometrial cancer: a pre-specified subgroup analysis from the phase 3 ENGOT … A Pérez Fidalgo, I Vergote, E Hamilton, G Valabrega, T Van Gorp, ... International Journal of Gynecologic Cancer 33 (Suppl 3), A7-A8, 2023 | 2 | 2023 |
| # 264 Long-term follow up of selinexor maintenance for patients with TP53wt advanced or recurrent endometrial cancer: a pre-specified subgroup analysis from the phase 3 ENGOT … AP Fidalgo, I Vergote, E Hamilton, G Valabrega, T Van Gorp, J Sehouli, ... International Journal of Gynecologic Cancer 33 (Suppl 3), 2023 | | 2023 |
| # 265 ENGOT-EN20/GOG-3083/XPORT-EC-042 a phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy for patients with P53 wild … I Vergote, MR Mirza, RJ Coleman, JA Pérez-Fidalgo, BJ Monk, ... International Journal of Gynecologic Cancer 33 (Suppl 3), 2023 | | 2023 |
| # 471 PARP-inhibitors can be applied together with tumor treating fields (TTFields) to prolong survival in an ovarian cancer mouse model Y Berckmans, R Wouters, G Thirion, K Vandenbrande, I Vergote, ... International Journal of Gynecologic Cancer 33 (Suppl 3), 2023 | | 2023 |
| # 479 The potential of anti-TIM3 in an ovarian cancer mouse model Y Berckmans, A Vankerckhoven, AA Caro, G Thirion, K Vandenbrande, ... International Journal of Gynecologic Cancer 33 (Suppl 3), 2023 | | 2023 |
| # 528 Efficacy of subsequent chemotherapy followed by PARP inhibitor maintenance in patients with advanced ovarian cancer in the phase III PAOLA-1/ENGOT-Ov25 trial C Marth, MA Mouret-Reynier, D Lorusso, C Cropet, P Harter, E Guerra, ... International Journal of Gynecologic Cancer 33 (Suppl 3), 2023 | 2 | 2023 |
| # 850 First experience with intra-abdominal 224radium-labelled microparticles (radspherin) after cytoreductive surgery for peritoneal metastasis in recurrent epithelial ovarian … Y Wang, E Van Nieuwenhuysen, T Skeie-Jensen, T Van Gorp, AK Aksnes, ... International Journal of Gynecologic Cancer 33 (Suppl 3), 2023 | | 2023 |
| 000125 THE ROLE OF WT1 GENE IN THE CARCINOGENESIS OF UTERINE SARCOMAS A Coosemans, SA Nik, S Caluwaerts, L Verbist, V Schelfhout, E de Jonge, ... International Journal of Gynecological Cancer 15 (Suppl 2), 87-88, 2005 | | 2005 |
| 000126 THE VALUE OF [18F] FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN PLACENTAL SITE TROFO-BLAST TUMOR A Coosemans, PH Moerman, H Hellemans, S Ceyssens, I Vergote, ... International Journal of Gynecological Cancer 15 (Suppl 2), 88-88, 2005 | | 2005 |
| 000184 PERITONEAL TUBERCULOSIS MIMICKING ADVANCED OVARIAN CARCINOMA: A CASE REPORT V Vandenbroucke, PH Moerman, F Ulens, I Vergote, F Amant International Journal of Gynecological Cancer 15 (Suppl 2), 102-102, 2005 | | 2005 |
| 0002 CHANCES FOR ADDITIONAL METASTASES IN VULVAR CANCER PATIENTS WITH A POSITIVE SENTINEL LYMPH NODE (SN) M Oonk, J De Hullu, A Ansink, I Vergote, R Verheijen, A Maggioni, ... International Journal of Gynecological Cancer 15 (Suppl 2), 51-51, 2005 | 2 | 2005 |
| 000283 THE PEDICLE ARTERY SIGN BASED ON TRANSVAGINAL COLOR DOPPLER IMAGING MAY IMPROVE ENDOMETRI-AL ASSESSMENT IN BREAST CANCER PATIENTS TREATED WITH TAMOXIFEN D Timmerman, L Morales, ML Konstantinovic, C Van Holsbeke, ... International Journal of Gynecological Cancer 15 (Suppl 2), 130-130, 2005 | | 2005 |
| 000285 LAPAROSCOPIC PARA-AORTIC LYMPHADENECTOMY AS STAGING PROCEDURE IN PATIENTS WITH CERVICAL CARCINOMA STAGE IB2-IIIB DG Mortier, F Amant, P Neven, P Berteloot, E Van Limbergen, I Vergote International Journal of Gynecological Cancer 15 (Suppl 2), 130-130, 2005 | | 2005 |
| 000297 PHASE I STUDY OF LIPOSOMAL DOXORUBICIN COMBINED WITH GEMCITABINE IN RECURRENT OVARIAN CANCER I Vergote, JF Baurain, E Joosens, F Amant, M Van Gramberen, P Berteloot International Journal of Gynecological Cancer 15 (Suppl 2), 133-134, 2005 | | 2005 |
| 000334 LAPAROSCOPIC ASSISTED VAGINAL HYSTERECTOMY OR ABDOMINAL HYSTERECTOMY IN CLINICAL FIGO STAGE I OR IIA ENDOMETRIAL CANCER S Lambrechts, T Van Gorp, F Amant, P Neven, P Berteloot, I Vergote International Journal of Gynecological Cancer 15 (Suppl 2), 143-143, 2005 | | 2005 |
| 00037 BREAST CANCER: WHAT ABOUT THE NON-SENTINEL LYMPH NODES IN 85 WOMEN WITH A CT1 BREAST CANCER AND A POSITIVE SENTINEL LYMPH NODE? A Van Wijck, P Neven, F Amant, K Leunen, A Smeets, S Marquette, ... International Journal of Gynecological Cancer 15 (Suppl 2), 61-61, 2005 | | 2005 |
| 00038 POTENTIAL ROLE OF PET-CT IN THE PREOPERATIVE STAGING OF LOCALLY ADVANCED BREAST CANCER I Segaert, P Neven, S Ceyssens, W De Wever, F Amant, P Berteloot, ... International Journal of Gynecological Cancer 15 (Suppl 2), 61-62, 2005 | | 2005 |
